August 9, 2012 — A new formulation of trastuzumab (Herceptin) that can be given as a subcutaneous injection is just as effective as standard intravenous (IV) trastuzumab, and takes just minutes ...

has approved Herceptin Hylecta™ (trastuzumab and hyaluronidase-oysk) for subcutaneous (under the skin) injection for the treatment of certain people with HER2-positive early breast cancer (node ...

and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection for the treatment of early and metastatic HER2-positive breast cancer. “This ...

Trastuzumab (Herceptin ... time and pharmacy workflow served as secondary endpoints. The subcutaneous injection significantly reduced time in the treatment chair for patients compared with ...

13, 2018 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) announced today that Health Canada has approved a subcutaneous ... injection and demonstrated comparable safety and efficacy to HERCEPTIN ...

Phesgo comes in a single-dose vial and can be dosed as a subcutaneous injection, while at the moment breast cancer patients the two anti-HER2 drugs separately receive Herceptin as a subcutaneous ...

Herceptin SC is given as a subcutaneous injection (under the skin) over 2 to 5 minutes every three weeks. More instructions can be found in Section 4. How do I use Herceptin SC? in the full CMI.

Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad ...

Trastuzumab is a type of targeted cancer drug called a ... You usually have injections under the skin (subcutaneous injection) into the stomach, thigh or top of your arm. You might have stinging or a ...

Subcutaneous administration of trastuzumab/pertuzumab could save breast cancer patients and healthcare providers substantial amounts of time compared with intravenous ...

2 Slamon D et al. Adjuvant Trastuzumab in HER2-Positive Breast Cancer. N Engl J Med 2011; 365:1273-83. 3 Pivot, Semiglazov et al. Subcutaneous injection of trastuzumab – analysis of ...